Euroopan unioni - islanti - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorrhagics - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - gabapentinum inn - filmuhúðuð tafla - 600 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - gabapentinum inn - hart hylki - 400 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - gabapentinum inn - hart hylki - 400 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

sanofi-aventis norge as - amiodaronum hýdróklóríð - tafla - 200 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

sanofi-aventis norge as - amiodaronum hýdróklóríð - tafla - 100 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

octapharma ab - factor ii human; factor vii human; factor ix human; factor x human; protein c; protein s - innrennslisstofn og leysir, lausn - 1000 a.e.

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - verapamilum hýdróklóríð - forðatafla - 200 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

prothya biosolutions netherlands b.v. - factor ii human; factor vii human; factor ix human; factor x human - stungulyfsstofn og leysir, lausn - 500 a.e.

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - gabapentinum inn - hart hylki - 300 mg